COMP <GO>
ROIV vs LLY // FORWARD P/E MULTIPLE
Roivant Sciences Ltd. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ROIV 2
— LLY 12
▲ FORWARD P/E MULTIPLE LEADER: LLY
LAST: $36.91 (-1.63%) • MKT CAP: $27.10B
forward-pe
28.0x
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
forward-pe
26.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ROIV VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ROIV | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 83.64% | -42.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -14.00% | 32.36% | -46.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.80% | 2.30% | -5.10 | LLY | /fcf-yield <GO> |
| Operating Margin | -60.00% | 40.21% | -100.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 31.90% | -91.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 45.51% | -110.51 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 9.29 | +16.71 | ROIV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 9/9 | -6.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.77% | +0.13 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.3 | 77.9 | -23.59 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.51 | +0.49 | ROIV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 28.0x | 26.3x | +1.75 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $27.10B | $1.33T | -$1.31T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ROIV REV | LLY REV | ROIV GROSS % | LLY GROSS % | ROIV FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.3M | $65.18B | 44.0% | 83.0% | -$758.6M | $16.81B |
| FY 2024 | $29.1M | $45.04B | 44.0% | 81.3% | -$844.0M | $8.82B |
| FY 2023 | $32.7M | $34.12B | 44.0% | 79.3% | -$766.7M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ROIV // BETA 1.00
LLY // BETA 0.51